What is Glutathione?
Glutathione is an endogenous tripeptide involved in redox biology. A six-month oral-supplement trial measured glutathione stores in several body compartments.
Biological role or research focus
Glutathione stores and supplementation research.
Biomarker changes are different from demonstrated disease prevention, improved survival, or broad “detox” benefits.
Role reference: Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. · 2015 ↗
Names you may encounter
GSH · Reduced glutathione
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Endogenous antioxidant tripeptide
- Research focus
- Glutathione stores and supplementation research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Glutathione FDA approved?
- No. No FDA-approved drug contains Glutathione. FDA lists it in 503A category 1: pharmacies may compound it while FDA evaluates it. Source ↗
- Is Glutathione safe?
- Glutathione is a natural antioxidant tripeptide. Oral supplement trials exist, but intravenous use lacks safety data, and in 2026 contaminated compounded injections made dozens of people ill. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Glutathione banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Glutathione?
- Yes. Our records list 5 FDA actions naming it, most recently on September 13, 2026: Centric Compounding (Houston, TX) recalled glutathione and two other injectable products nationwide for elevated endotoxin after nine adverse event reports. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Oral glutathione and body stores (2015) | Human randomized trial | 54 nonsmoking adults. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2015
Oral glutathione and body stores
What did this publication test, and what did it find?
- Population / model
- 54 nonsmoking adults.
- Study design
- Six-month randomized double-blind placebo-controlled oral-supplementation study, with washout measurements.
- Main finding
- Glutathione increased in measured blood and cellular compartments in the supplemented groups and returned toward baseline after washout.
- Limits & context
- Biomarker changes are different from demonstrated disease prevention, improved survival, or broad “detox” benefits.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
32 registered studies name Glutathione as an intervention among the 100 most recently updated of 276 search results; 18 are recruiting or under way, 2 have not started recruiting yet, 9 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 32 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The antioxidant glutathione. ↗
Vitamins and hormones · 2023 · Journal Article, Research Support, Non-U.S. Gov't
Glutathione as a skin-lightening agent and in melasma: a systematic review. ↗
International journal of dermatology · 2025 Jun · Journal Article, Systematic Review
Glutathione. ↗
The arabidopsis book · 2011 · Journal Article
Read available full text ↗
Glutathione and peroxisome redox homeostasis. ↗
Redox biology · 2023 Nov · Journal Article, Review, Research Support, Non-U.S. Gov't
Read available full text ↗
Risks & interactions
Glutathione is a natural antioxidant tripeptide. Oral supplement trials exist, but intravenous use lacks safety data, and in 2026 contaminated compounded injections made dozens of people ill.
A six-month randomized oral trial and other short trials exist. Reviews found no studies of intravenous glutathione for skin lightening and no safety data on long-term intravenous use for any purpose.
Take extra care with: Heart or blood pressure problemsCancer, now or in the past
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Contaminated injections: in 2026 FDA and CDC linked fever, chills, low blood pressure and shock-like reactions in dozens of people to compounded glutathione made from supplement-grade ingredient with high endotoxin levels; some were hospitalized
- Intravenous use for skin lightening: inadequate safety data; a systematic review called it contraindicated because of side effects and lack of benefit
- Reviewers raised a theoretical concern that skin lightening could raise the risk of sun-related skin cancer
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA alert: supplement-grade glutathione in injectables (August 2026) ↗ · CDC: adverse events linked to injectable glutathione (September 2026) ↗ · Randomized trial of oral glutathione on body stores (2015) ↗ · Intravenous glutathione for skin lightening: inadequate safety data (2016) ↗ · Glutathione for skin lightening and melasma: systematic review (2025) ↗
Safety & what remains unknown
Safety and tolerability depend on the route and preparation. Oral findings cannot establish infusion safety.
Evidence boundaries
Biomarker changes are different from demonstrated disease prevention, improved survival, or broad “detox” benefits.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug with glutathione as the active ingredient was found. Glutathione disulfide is one component of BSS Plus, an FDA-approved ophthalmic irrigation solution (NDA 018469). source - FDA compounding (503A bulk list)
- Category 1 (can be compounded while FDA reviews it)
Listed in 503A category 1 ("Glutathione"), meaning FDA is evaluating it and does not intend to take action against 503A compounders using it, provided interim-policy conditions are met. source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
FDA actions
- FDA warning letter to an outsourcing facility (GenoGenix) naming "Glutathione Magnesium" among compounded products with labeling violations. (2026-01-20) source
- Victory Medical Center Pharmacy (Austin, TX) recalled lots of compounded injectable glutathione to the patient level after testing found elevated bacterial endotoxin. (2026-08-05) source
- Optimal Balance Pharmacy (Houston, TX) recalled a lot of compounded injectable glutathione for elevated endotoxin, reporting fever, chills and allergic-type reactions. (2026-08-19) source
- FDA alert: at least 30 patients had adverse events, including shock and sepsis-like symptoms, after intravenous glutathione compounded from a dietary-supplement-grade ingredient (Medisca lot 229536); FDA told compounders not to use supplement-grade glutathione for injectables. (2026-08-27) source
- Centric Compounding (Houston, TX) recalled glutathione and two other injectable products nationwide for elevated endotoxin after nine adverse event reports. (2026-09-13) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The featured evidence concerns an oral preparation. It does not establish equivalent outcomes for intravenous, inhaled, or topical products.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The study tested whether oral supplementation changes measured glutathione concentrations. A higher biomarker concentration does not automatically imply prevention or treatment of a disease.
Questions worth asking
- Does this trial prove a detox or disease-prevention benefit?
- What material, population, and route were actually studied?
- Biomarker changes are different from demonstrated disease prevention, improved survival, or broad “detox” benefits.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does this trial prove a detox or disease-prevention benefit?
No. Its principal observations concern glutathione stores and related laboratory measures.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
